Coronavirus disease 2019 (COVID-19) is a global pandemic with over 9.1 million laboratory-confirmed cases and more than 473 000 deaths reported worldwide since first being identified in China in December 2019.1 In the United States, current projections indicate that the death toll will exceed 180 000 by October 2020.2 COVID-19 is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although most patients with COVID-19 recover without complications, a unique subset of patients develop severe disease. Recent data suggest that patients with severe COVID-19 account for only 6% to 15% of all cases but make up approximately 60% of all intensive care unit (ICU) admissions for the disease.3, 4 Complications of COVID-19 include acute respiratory distress syndrome (ARDS), septic shock, and multiorgan failure. As of June 2020, there were no US Food and Drug Administration (FDA)–approved drugs for the treatment of COVID-19. Clinical...
Skip Nav Destination
Article navigation
Fall 2020
Drug Update|
September 15 2020
COVID-19 Therapeutics: Making Sense of It All
Lolade S. Bakare, PharmD;
Lolade S. Bakare, PharmD
Lolade S. Bakare is PGY-1 Pharmacy Resident, Cleveland Clinic Martin Health, Stuart, Florida.
Search for other works by this author on:
John M. Allen, PharmD, BCPS, BCCCP
John M. Allen, PharmD, BCPS, BCCCP
John M. Allen is Clinical Assistant Professor, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, 6550 Sanger Rd, Ste 420G, Orlando, FL 32827 ([email protected]).
Search for other works by this author on:
AACN Adv Crit Care (2020) 31 (3): 239–249.
Citation
Lolade S. Bakare, John M. Allen; COVID-19 Therapeutics: Making Sense of It All. AACN Adv Crit Care 15 September 2020; 31 (3): 239–249. doi: https://doi.org/10.4037/aacnacc2020792
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access